首页> 外文期刊>Acta Cardiologica >Cardiopulmonary involvement in Fabry's disease.
【24h】

Cardiopulmonary involvement in Fabry's disease.

机译:心肺参与法布里氏病。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Fabry's disease is an X-linked lysosomal storage disease caused by deficiency of alpha-galactosidase A enzyme activity. Decreased enzyme activity leads to accumulation of glycosphingolipid in different tissues, including endothelial and smooth-muscle cells and cardiomyocytes. OBJECTIVES: There is controversial data on cardiopulmonary involvement in Fabry's disease, because many reports are based on small and selected populations with Fabry's disease. Furthermore, the aetiology of cardiopulmonary symptoms in Fabry's disease is poorly understood. METHODS: We studied cardiopulmonary involvement in seventeen patients with Fabry's disease (20-65 years, 6 men) using ECG, bicycle stress, cardiac magnetic resonance imaging, spirometry, diffusing capacity and pulmonary high-resolution computed tomography (HRCT) tests. Cardiopulmonary symptoms were compared to observed parameters in cardiopulmonary tests. RESULTS: Left ventricular hypertrophy (LVH) and reduced exercise capacity are the most apparent cardiac changes in both genders with Fabry's disease. ECG parameters were normal when excluding changes related to LVH. Spirometry showed mild reduction in vital capacity and forced expiratory volume in one second (FEV I), and mean values in diffusing capacity tests were within normal limits. Generally, only slight morphological pulmonary changes were detected using pulmonary HRCT, and they were not associated with changes in pulmonary function. The self-reported amount of pulmonary symptoms associated only with lower ejection fraction (P < 0.001) and longer QRS-duration (P = 0.04) of all measured cardiopulmonary parameters, whereas cardiac symptoms have no statistically significant association with any of these parameters. CONCLUSION: LVH and reduced exercise capacity are the most apparent cardiopulmonary changes in Fabry's disease but they have only a minor association to cardiopulmonary symptoms.Therefore, routine cardiopulmonary evaluation in Fabry's disease using echocardiography is maybe enough when integrated to counselling for aerobic exercise training.
机译:背景:法布里氏病是由α-半乳糖苷酶A酶活性不足引起的X连锁溶酶体贮积病。酶活性的降低导致糖鞘脂在不同组织中的积累,这些组织包括内皮细胞和平滑肌细胞以及心肌细胞。目的:关于心肺参与法布里氏病的研究存在争议的数据,因为许多报道都是基于小型且选定的法布里氏病人群。此外,对法布里氏病的心肺症状的病因了解甚少。方法:我们使用心电图,自行车压力,心脏磁共振成像,肺活量测定,扩散能力和肺高分辨率计算机断层扫描(HRCT)测试,研究了17名法布里氏病(20-65岁,6名男性)患者的心肺功能。将心肺症状与心肺测试中观察到的参数进行比较。结果:左室肥大(LVH)和运动能力下降是法布里氏病患者中最明显的心脏改变。当排除与LVH相关的变化时,ECG参数正常。肺活量测定法显示一秒钟内肺活量和强制呼气量有轻度降低(FEV I),扩散能力测试的平均值在正常范围内。通常,使用肺部HRCT仅能检测到轻微的形态学肺部改变,并且与肺功能的改变无关。自我报告的肺部症状数量仅与所有测得的心肺参数的较低射血分数(P <0.001)和较长QRS持续时间(P = 0.04)相关,而心脏症状与这些参数均无统计学意义。结论:LVH和运动能力下降是法布里氏病最明显的心肺变化,但与心肺症状的关系很小,因此,将超声心动图对法布里氏病进行常规心肺评估与有氧运动训练咨询相结合可能就足够了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号